Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma
Oxaliplatin-based chemotherapy is used to treat patients with esophageal adenocarcinoma (EAC), but no biomarkers are currently available for patient selection. We performed a prospective, clinical trial to identify potential biomarkers associated with clinical outcomes. Tumor tissue was obtained fro...
Main Authors: | MacGregor, T, Carter, R, Gillies, R, Findlay, J, Kartsonaki, C, Castro-Giner, F, Sahgal, N, Wang, L, Chetty, R, Maynard, N, Cazier, J, Buffa, F, McHugh, P, Tomlinson, I, Middleton, M, Sharma, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Nature Publishing Group
2018
|
Similar Items
-
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma
by: T. P. MacGregor, et al.
Published: (2018-05-01) -
Tumour expression of the DNA repair protein, XPF, predicts pathological response to neoadjuvant oxaliplatin chemotherapy in oesophageal cancer
by: Gillies, R, et al.
Published: (2011) -
XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
by: Hatch, S, et al.
Published: (2014) -
XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.
by: Hatch, S, et al.
Published: (2014) -
Joint molecule resolution requires the redundant activities of MUS-81 and XPF-1 during Caenorhabditis elegans meiosis.
by: Nigel J O'Neil, et al.
Published: (2013-01-01)